Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone
Jessica G. Shantha,
John G. Mattia,
Augustine Goba,
Kayla G. Barnes,
Faiqa K. Ebrahim,
Colleen S. Kraft,
Brent R. Hayek,
Jessica N. Hartnett,
Jeffrey G. Shaffer,
John S. Schieffelin,
John D. Sandi,
Mambu Momoh,
Simbirie Jalloh,
Donald S. Grant,
Kerry Dierberg,
Joyce Chang,
Sharmistha Mishra,
Adrienne K. Chan,
Rob Fowler,
Tim O'Dempsey,
Erick Kaluma,
Taylor Hendricks,
Roger Reiners,
Melanie Reiners,
Lowell A. Gess,
Kwame ONeill,
Sarian Kamara,
Alie Wurie,
Mohamed Mansaray,
Nisha R. Acharya,
William J. Liu,
Sina Bavari,
Gustavo Palacios,
Moges Teshome,
Ian Crozier,
Paul E. Farmer,
Timothy M. Uyeki,
Daniel G. Bausch,
Robert F. Garry,
Matthew J. Vandy,
Steven Yeh
Affiliations
Jessica G. Shantha
Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States; University of California San Francisco, Proctor Foundation, San Francisco, CA, United States
John G. Mattia
Lunsar Baptist Eye Hospital, Port Loko, Sierra Leone
Augustine Goba
Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone
Kayla G. Barnes
Department of Organismic and Evolutionary Biology, Harvard University, United States; Broad Institute of MIT and Harvard, Cambridge, MA, United States
Faiqa K. Ebrahim
World Health Organization, Geneva, Switzerland
Colleen S. Kraft
Department of Pathology and Laboratory Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, United States
Brent R. Hayek
Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States
Jessica N. Hartnett
Tulane University School of Medicine, New Orleans, LA, United States
Jeffrey G. Shaffer
Department of Biostatistics and Bioinformatics, Tulane School of Public Health, New Orleans, LA, United States
John S. Schieffelin
Tulane University School of Medicine, New Orleans, LA, United States
John D. Sandi
Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone
Mambu Momoh
Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone
Simbirie Jalloh
Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone
Donald S. Grant
Kenema Government Hospital Lassa Hemorrhagic Fever Laboratory, Kenema, Sierra Leone; Department of Community Health, University of Sierra Leone, Freetown, Sierra Leone
Kerry Dierberg
Partners in Health, Boston, MA, United States
Joyce Chang
Partners in Health, Boston, MA, United States
Sharmistha Mishra
University of Toronto, Toronto, ON, Canada
Adrienne K. Chan
University of Toronto, Toronto, ON, Canada
Rob Fowler
University of Toronto, Toronto, ON, Canada
Tim O'Dempsey
University of Liverpool, Liverpool, United Kingdom
Erick Kaluma
Comprehensive Program for Ebola Survivors, Freetown, Sierra Leone
Taylor Hendricks
Comprehensive Program for Ebola Survivors, Freetown, Sierra Leone
Roger Reiners
Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone
Melanie Reiners
Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone
Lowell A. Gess
Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone
Kwame ONeill
Ministry of Health and Sanitation, Sierra Leone
Sarian Kamara
Ministry of Health and Sanitation, Sierra Leone
Alie Wurie
Ministry of Health and Sanitation, Sierra Leone
Mohamed Mansaray
Sierra Leone Association of Ebola Survivors, Freetown, Sierra Leone
Nisha R. Acharya
University of California San Francisco, Proctor Foundation, San Francisco, CA, United States
William J. Liu
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
Sina Bavari
United Stated Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
Gustavo Palacios
United Stated Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
Moges Teshome
Lowell and Ruth Gess Eye Hospital, Freetown, Sierra Leone; Christian Blind Mission International, Washington, D.C., United States
Ian Crozier
Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
Paul E. Farmer
Partners in Health, Boston, MA, United States
Timothy M. Uyeki
Centers for Disease Control and Prevention, Atlanta, GA, United States
Daniel G. Bausch
UK Public Health Rapid Support Team Public Health England/London School of Hygiene and Tropical Medicine, London, United Kingdom
Robert F. Garry
Tulane University School of Medicine, New Orleans, LA, United States
Matthew J. Vandy
Ministry of Health and Sanitation, Sierra Leone
Steven Yeh
Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States; Emory Global Health Institute, Emory University, Atlanta, GA, United States; Corresponding author at: 1365B Clifton Rd. NE, Atlanta, GA 30322, United States.
Background: Ebola virus disease (EVD) survivors are at risk for uveitis during convalescence. Vision loss has been observed following uveitis due to cataracts. Since Ebola virus (EBOV) may persist in the ocular fluid of EVD survivors for an unknown duration, there are questions about the safety and feasibility of vision restorative cataract surgery in EVD survivors. Methods: We conducted a cross-sectional study of EVD survivors anticipating cataract surgery and patients with active uveitis to evaluate EBOV RNA persistence in ocular fluid, as well as vision outcomes post cataract surgery. Patients with aqueous humor that tested negative for EBOV RNA were eligible to proceed with manual small incision cataract surgery (MSICS). Findings: We screened 137 EVD survivors from June 2016 – August 2017 for enrolment. We enrolled 50 EVD survivors; 46 with visually significant cataract, 1 with a subluxated lens, 2 with active uveitis and 1 with a blind painful eye due to uveitis. The median age was 24.0 years (IQR 17–35) and 35 patients (70%) were female. The median logMAR visual acuity (VA) was 3.0 (Snellen VA Hand motions; Interquartile Range, IQR: 1.2-3.0, Snellen VA 20/320 – Hand motions). All patients tested negative for EBOV RNA by RT-PCR in aqueous humor/vitreous fluid and conjunctiva at a median of 19 months (IQR 18-20) from EVD diagnosis in Phase 1 of ocular fluid sampling and 34 months (IQR 32-36) from EVD diagnosis in Phase 2 of ocular fluid sampling. Thirty-four patients underwent MSICS, with a preoperative median VA improvement from hand motions to 20/30 at three-month postoperative follow-up (P < 0.001). Interpretation: EBOV persistence by RT-PCR was not identified in ocular fluid or conjunctivae of fifty EVD survivors with ocular disease. Cataract surgery can be performed safely with vision restorative outcomes in patients who test negative for EBOV RNA in ocular fluid specimens. These findings impact the thousands of West African EVD survivors at-risk for ocular complications who may also require eye surgery during EVD convalescence. Keywords: Ebola virus disease, Ebolavirus, Ophthalmology, Uveitis, Global Health, Cataract